Delipidation of a hepadnavirus: Viral inactivation and vaccine development

Cham, Bill E.; Vickery, Karen; Tohidi-Esfahani, R.; Cossart, Yvonne E.

doi:10.1016/j.jviromet.2006.05.027

Cited by 8 publications

(7 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Glutaraldehydeinactivated DHBV and BRSV developed virus-specific antibodies, but ducks vaccinated with glutaraldehyde-inactivated DHBV and lambs vaccinated with glutaraldehyde-inactivated BRSV were not fully protected against viremia following challenge. This indicates that there was no induction of protective immunity in these animals [4,51].…”

Section: Glutaraldehydementioning

confidence: 90%

“…Therefore, the induction of a protective immune response can be more of a problem with glutaraldehydeinactivated virus vaccines. Duck HBV (DHBV) and bovine RSV (BRSV) are viruses for which the use of glutaraldehyde has been tested for the production of a KV vaccine [4,51]. Glutaraldehydeinactivated DHBV and BRSV developed virus-specific antibodies, but ducks vaccinated with glutaraldehyde-inactivated DHBV and lambs vaccinated with glutaraldehyde-inactivated BRSV were not fully protected against viremia following challenge.…”

Section: Glutaraldehydementioning

confidence: 99%

“…First, virus inactivation may turn out to be incomplete with outbreaks after vaccination as a consequence [1][2][3]. Second, the viral-neutralizing epitopes may be destroyed during inactivation, resulting in a poor neutralizing antibody response and a poor protection on challenge [4][5][6]. Therefore, efficient quality control of the inactivated antigen is necessary to evaluate virus inactivation and the effect of the inactivation procedure on neutralizing epitopes.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Inactivated virus vaccines from chemistry to prophylaxis: merits, risks and challenges

Delrue

Verzele

Madder

et al. 2012

Expert Review of Vaccines

161

150

View full text Add to dashboard Cite

The aim of this review is to make researchers aware of the benefits of an efficient quality control system for prediction of a developed vaccine's efficacy. Two major goals should be addressed when inactivating a virus for vaccine purposes: first, the infectious virus should be inactivated completely in order to be safe, and second, the viral epitopes important for the induction of protective immunity should be conserved after inactivation in order to have an antigen of high quality. Therefore, some problems associated with the virus inactivation process, such as virus aggregate formation, protein crosslinking, protein denaturation and degradation should be addressed before testing an inactivated vaccine in vivo

show abstract

Section: Glutaraldehydementioning

confidence: 90%

Section: Glutaraldehydementioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Inactivated virus vaccines from chemistry to prophylaxis: merits, risks and challenges

Delrue

Verzele

Madder

et al. 2012

Expert Review of Vaccines

161

150

View full text Add to dashboard Cite

show abstract

“…Recently it was shown that a specific solvent system disrupted the lipid envelope of duck hepatitis B virus without denaturing proteins of the virus. Delipidation completely inactivated the duck hepatitis B virus which modified the whole virion antigens which were retained in an appropriate form to induce immunity [25]. SRGs may have similar effects of delipidation of viral particles.…”

Section: Groups Treatmentsmentioning

confidence: 99%

Solasodine Rhamnosyl Glycosides Cause Apoptosis in Cancer Cells. Do They Also Prime the Immune System Resulting in Long-Term Protection against Cancer?

Cham

Chase

2012

Planta Med

View full text Add to dashboard Cite

Solasodine rhamnosyl glycosides (SRGs) induce apoptosis in a wide variety of cancer cells and are more effective than many well-established anticancer agents. Combination therapy of SRGs with cisplatin treats cisplatin-resistant cells such as lung cancer and breast cancer cells. Anticancer therapies with SRGs have been used intravenously, intraperitoneally, intralesionally, orally, and topically. Data is now presented that in addition to apoptosis and, perhaps as a consequence thereof, SRGs also have an effect of stimulating lasting immunity against cancer as shown with a mouse model and the terminal cancer Sarcoma 180. Mice were inoculated i. p. with Sarcoma 180. Groups of animals were administered SRGs half an hour after Sarcoma 180 inoculation. Mice treated with Sarcoma 180 but not with SRGs all died within 20 days. Four doses of SRGs caused total remission of Sarcoma 180 activity. Mice that went into remission were then reinoculated 20 days later with the cancer. Ten of twelve SRGs cured-animals were resistant to reinduction of terminal doses of the cancer. In comparison, twelve of twelve mice treated with SRGs without initial Sarcoma 180 activity but which were inoculated with Sarcoma 180 cells 20 days later, all died. In addition to apoptosis, SRGs stimulate lasting immunity against cancer. SRGs could play an important role in clinical management of diseases such a malignancy and also be used as a preventative therapy.

show abstract

“…Pathogens with exposed lipid membranes are more susceptible to disinfectants including detergents and other solvents [23][24][25] . Organic solvents render many pathogens non-infectious by solubilizing and disrupting their lipid membranes or envelopes [26][27][28] , and inactivation of pathogens by organic solvents has been leveraged for vaccine development [29][30][31][32] , transfusion fluids [33][34][35][36] , and sanitation [37][38][39] . In systems biology studies of pathogenic bacteria and viruses, it would be highly efficient to both inactivate pathogens and extract the molecular components needed for proteomic, metabolomic, and lipidomic analyses in a single step.…”

mentioning

confidence: 99%

MPLEx: a method for simultaneous pathogen inactivation and extraction of samples for multi-omics profiling

Burnum-Johnson

Kyle

Eisfeld

et al. 2017

Analyst

View full text Add to dashboard Cite

The continued emergence and spread of infectious agents is of great concern, and systems biology approaches to infectious disease research can advance our understanding of host-pathogen relationships and facilitate the development of new therapies and vaccines. Molecular characterization of infectious samples outside of appropriate biosafety containment can take place only subsequent to pathogen inactivation. Herein, we describe a modified Folch extraction using chloroform/methanol that facilitates the molecular characterization of infectious samples by enabling simultaneous pathogen inactivation and extraction of proteins, metabolites, and lipids for subsequent mass spectrometry-based multi-omics measurements. This single-sample metabolite, protein and lipid extraction (MPLEx) method resulted in complete inactivation of clinically important bacterial and viral pathogens with exposed lipid membranes, including Yersinia pestis, Salmonella Typhimurium, and Campylobacter jejuni in pure culture, and Yersinia pestis, Campylobacter jejuni, and West Nile, MERS-CoV, Ebola, and influenza H7N9 viruses in infection studies. In addition, >99% inactivation, which increased with solvent exposure time, was also observed for pathogens without exposed lipid membranes including community-associated methicillin-resistant Staphylococcus aureus, Clostridium difficile spores and vegetative cells, and adenovirus type 5. The overall pipeline of inactivation and subsequent proteomic, metabolomic, and lipidomic analyses was evaluated using a human epithelial lung cell line infected with wild-type and mutant influenza H7N9 viruses, thereby demonstrating that MPLEx yields biomaterial of sufficient quality for subsequent multi-omics analyses. Based on these experimental results, we believe that MPLEx will facilitate systems biology studies of infectious samples by enabling simultaneous pathogen inactivation and multi-omics measurements from a single specimen with high success for pathogens with exposed lipid membranes.

show abstract

Delipidation of a hepadnavirus: Viral inactivation and vaccine development

Cited by 8 publications

References 16 publications

Inactivated virus vaccines from chemistry to prophylaxis: merits, risks and challenges

Inactivated virus vaccines from chemistry to prophylaxis: merits, risks and challenges

Solasodine Rhamnosyl Glycosides Cause Apoptosis in Cancer Cells. Do They Also Prime the Immune System Resulting in Long-Term Protection against Cancer?

MPLEx: a method for simultaneous pathogen inactivation and extraction of samples for multi-omics profiling

Contact Info

Product

Resources

About